1541421591275491328

#AACRMalignantLymphoma: Gamida Cell’s Phase 1/2 study, now open for enrollment, is evaluating #NAMenabled NK cell therapy candidate #GDA201 as new treatment option for patients with #follicularlyphoma and #diffuselargBcelllymphoma. https://t.co/tmibk8fO1t
#NKCellTherapy https://t.co/gNZbZQak1i

Send us a message